Oxaliplatin-induced hypersensitivity reaction: underlying mechanisms and management

References

• Zanotti KM, Markman M. Prevention and management of antineoplastic induced hypersensitivity reactions. Drug Saf. 2001;24:767–79.
   PubMed Web of Science ®Google Scholar
• Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol. 2009;102(3):179–87.
   PubMed Web of Science ®Google Scholar
• Gowda A, Goel R, Berdzik J, Leichman CG, Javle M. Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology (Williston Park). 2004;18(13):1671–5.
   PubMed Web of Science ®Google Scholar
• Wang JH, King TM, Chang MC, Hsu CW. Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis. World J Gastroenterol. 2012;18(38):5427–33.
   PubMed Web of Science ®Google Scholar
• Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer. 2003;89:477–81.
   PubMed Web of Science ®Google Scholar
• Lee MY, Yang MH, Liu JH, Yen CC, Lin PC, Teng HW, et al. Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer. 2007;15:89–93.
   PubMed Web of Science ®Google Scholar
• Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5):601–9.
   PubMed Web of Science ®Google Scholar
• James E, Podoltsev N, Salehi E, Curtis BR, Saif MW. Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect? Clin Colorectal Cancer. 2009;8:220–4.
   PubMed Web of Science ®Google Scholar
• Bautista MA, Stevens WT, Chen CS, Curtis BR, Aster RH, Hsueh CT. Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol. 2010;3:12.
   PubMed Web of Science ®Google Scholar
• Pichler WJ, Naisbitt DJ, Park BK. Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol. 2011;127(Suppl 3):S74–81.
   Google Scholar
• Koutras AK, Makatsoris T, Paliogianni F, Kopsida G, Onyenadum A, Gogos CA, et al. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology. 2004;67:179–82.
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F, Andre T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, et al. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer. 2005;41(15):2262–7.
   PubMed Web of Science ®Google Scholar
• Curtis BR, Kaliszewski J, Marques MB, Saif MW, Nabelle L, Blank J, et al. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol. 2006;81:193–8.
   PubMed Web of Science ®Google Scholar
• Shao YY, Hong RL. Fatal thrombocytopenia after oxaliplatin-based chemotherapy. Anticancer Res. 2008;28:3115–7.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Bruserud Y, Dahl O. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and hemolysis. Acta Oncol. 2001;40:882–3.
   PubMed Web of Science ®Google Scholar
• Teng CJ, Hsieh YY, Chen KW, Chao TC, Tzeng CH, Wang WS. Sudden-onset pancytopenia with intracranial hemorrhage after oxaliplatin treatment: a case report and literature review. Jpn J Clin Oncol. 2011;41:125–9.
   PubMed Web of Science ®Google Scholar
• Taleghani BM, Meyer O, Fontana S, Ahrens N, Novak U, Borner MM, et al. Oxaliplatin-induced immune pancytopenia. Transfusion. 2005;45(5):704–8.
   PubMed Web of Science ®Google Scholar
• Wang JH, King TM, Chang MC, Hsu CW. Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis. World J Gastroenterol. 2012;18(38):5427–33.
   PubMed Web of Science ®Google Scholar
• Syrigou E, Syrigos K, Saif MW. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep. 2008;8(1):56–62.
   PubMed Web of Science ®Google Scholar
• Seki K, Senzaki K, Tsuduki Y, Ioroi T, Fujii M, Yamauchi H, et al. Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci. 2011;8:210–5.
   PubMed Web of Science ®Google Scholar
• Parel M, Ranchon F, Nosbaum A, You B, Vantard N, Schwiertz V, et al. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol. 2014;15(1):1.
   PubMedGoogle Scholar
• Kim BH, Bradley T, Tai J, Budman DR. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology. 2009;76(4):231–8.
   PubMed Web of Science ®Google Scholar
• Chay WY, Chew L, Yeoh TT, Tan MH. An association between transient hypokalemia and severe acute oxaliplatinrelated toxicity predominantly in women. Acta Oncol. 2010;49:515–7.
   PubMed Web of Science ®Google Scholar
• Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S, et al. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol. 2011;16(3):244–9.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanism. Clin Sci (Lond). 1998;94(6):557–72.
   PubMed Web of Science ®Google Scholar
• Ghezzi P. Role of glutathione in immunity and inflammation in the lung. Int J Gen Med. 2011;4:105–13.
   PubMedGoogle Scholar
• Hadzic T, Li L, Cheng N, Walsh SA, Spitz DR, Knudson CM. The role of low molecular weight thiols in T lymphocyte proliferation and IL-2 secretion. J Immunol. 2005;175(12):7965–72.
   PubMed Web of Science ®Google Scholar
• Kuppner MC, Scharner A, Milani V, von Hesler C, Tschop KE, Heinz O, et al. Ifosfamide impairs the allostimulatory capacity of human dendritic cells by intracellular glutathione depletion. Blood. 2003;102(10):3668–74.
   PubMed Web of Science ®Google Scholar